By yourNEWS Media Newsroom
The U.S. Supreme Court on Wednesday, Oct. 21, rejected an emergency request from the Trump administration to enforce new restrictions on medical treatment for transgender inmates in federal prisons, leaving a lower court injunction in effect as a legal challenge proceeds.
The unsigned order provided no explanation for the decision. Justices Clarence Thomas and Samuel Alito indicated they would have granted the administration’s request, allowing the Federal Bureau of Prisons to implement the restrictions while the case moves through the courts.
The ruling does not resolve the underlying dispute over the administration’s authority to limit gender-transition procedures and related medical care in federal correctional facilities. Instead, it preserves the existing requirements while federal courts examine whether the Bureau of Prisons followed applicable law when adopting its new policy.
As NBC News reported, the administration sought emergency relief from an injunction that prevented prison officials from discontinuing hormone therapy, gender-transition surgeries and certain accommodations for inmates diagnosed with gender dysphoria.
The dispute originated with an executive order President Donald Trump signed on Jan. 20, 2025, directing federal agencies to recognize sex as a biological classification and revise policies permitting taxpayer-funded gender-transition treatments.
The order, titled “Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government,” instructed agencies to review federal programs and spending practices involving gender identity.
“Federal funds shall not be used to promote gender ideology. Each agency shall assess grant conditions and grantee preferences and ensure grant funds do not promote gender ideology,” the order stated.
Trump also directed the Justice Department to ensure that the Bureau of Prisons revised its medical policies to comply with the administration’s position.
“The Attorney General shall ensure that the Bureau of Prisons revises its policies concerning medical care to be consistent with this order, and shall ensure that no Federal funds are expended for any medical procedure, treatment, or drug for the purpose of conforming an inmate’s appearance to that of the opposite sex,” the directive stated.
Following the order, prison officials issued several policy announcements restricting gender-transition treatment and accommodations. The changes culminated in a policy issued in February 2026 that substantially limited the care available to transgender prisoners.
Under the revised policy, the Bureau of Prisons would no longer provide gender-transition surgeries, with exceptions for medical care addressing complications from procedures already performed. The agency also sought to discontinue hormone therapy for inmates diagnosed with gender dysphoria, including gradually ending treatment for individuals already receiving it.
Additional restrictions covered accommodations such as wigs, makeup, clothing and hair-removal products associated with an inmate’s gender identity. Prison officials maintained that psychiatric services, psychotherapy and other mental health interventions would remain available.
The administration argued that the changes were consistent with Trump’s executive order and reflected concerns about the medical evidence supporting certain gender-transition treatments. Justice Department attorneys also maintained that the Bureau of Prisons should have greater discretion over medical policies within federal correctional institutions.
Three transgender inmates challenged the restrictions in federal court, arguing that abruptly ending treatment would expose prisoners to serious medical and psychological consequences. Their lawsuit subsequently became a class action representing inmates diagnosed with gender dysphoria who were affected by the policy.
The plaintiffs contended that the government had adopted sweeping restrictions without adequately considering medical evidence, individual treatment requirements or the Bureau of Prisons’ previous experience providing such care.
The case, Kingdom v. Trump, was assigned to U.S. District Judge Royce C. Lamberth in Washington, D.C. Lamberth, who was appointed by President Ronald Reagan, issued orders blocking the restrictions while examining the agency’s decision-making process.
In a June 17 memorandum opinion, Lamberth determined that the plaintiffs had demonstrated grounds for preliminary relief. The judge focused on whether the Bureau of Prisons had adequately justified its departure from established practices and complied with federal administrative requirements.
The ruling questioned the agency’s treatment of scientific evidence and the consequences of withdrawing medical care from people who had previously received it. Lamberth found that the government had not adequately explained why it was abandoning existing approaches to treating gender dysphoria, particularly when medical professionals had documented risks associated with abruptly ending treatment.
The court concluded that the policy was likely arbitrary and capricious under the Administrative Procedure Act, which requires federal agencies to provide reasoned explanations for significant regulatory decisions.
The injunction directed prison officials to continue providing qualifying inmates with gender-affirming medications and accommodations consistent with the policies in place immediately before Trump’s January 2025 executive order.
The decision did not establish that every inmate requesting surgery or other treatment was automatically entitled to receive it. Individual medical decisions remained subject to applicable clinical requirements and the Bureau of Prisons’ previous treatment procedures.
The Justice Department subsequently asked the Supreme Court to suspend the injunction, arguing that the lower court had interfered with the administration’s ability to manage federal prisons and implement executive policy.
Federal attorneys maintained that the government faced difficulties enforcing its revised standards while the injunction remained in effect. They also questioned whether the evidence supported continuing treatments that the administration characterized as medically disputed.
The inmates opposing the emergency application argued that removing the injunction would create immediate risks for prisoners receiving ongoing treatment. They maintained that treatment interruptions could produce significant medical and mental health consequences and that the administration had not justified its decision under federal law.
The Supreme Court’s Wednesday order leaves Lamberth’s injunction in place without adopting either side’s full legal argument.
According to Associated Press coverage of the ruling, the Bureau of Prisons must continue complying with the lower court’s restrictions on implementing the new policy while the litigation proceeds. <Cite ref=”turn205747news18″/>
Thomas and Alito’s dissent from the emergency ruling indicates that they favored allowing the administration to enforce its policy during the legal proceedings. Neither justice provided a written explanation accompanying the order.
The absence of a detailed Supreme Court opinion means the decision offers limited guidance about how the justices might ultimately evaluate the legal questions if the dispute returns to the court through the ordinary appeals process.
The case involves competing interpretations of federal administrative authority, medical treatment requirements and the rights of incarcerated individuals.
Federal prison officials have responsibility for maintaining institutional safety, establishing medical policies and determining how available resources are used. At the same time, federal law requires prison systems to address serious medical needs and prohibits agencies from adopting policies that violate applicable procedural requirements.
The Eighth Amendment’s prohibition on cruel and unusual punishment also establishes constitutional limits on deliberate indifference to serious medical conditions among incarcerated individuals.
Although the present injunction focuses heavily on administrative law, questions about the medical treatment owed to prisoners remain relevant to the broader dispute.
Gender dysphoria is a recognized medical diagnosis involving clinically significant distress associated with incongruence between an individual’s gender identity and sex-related characteristics. Treatment approaches vary according to a patient’s circumstances and may include counseling, medication and other interventions.
The federal government’s former policies allowed healthcare professionals to evaluate such needs through individualized assessments. The administration’s revised approach would substantially restrict access to particular treatments regardless of some previously established medical recommendations.
The number of inmates potentially affected has also drawn attention. Federal data cited in reporting on the case indicate that more than 2,000 transgender individuals were held in federal custody during 2025, although estimates vary depending on the reporting period and methods used to identify the population.
Approximately 600 federal inmates were receiving hormone therapy in 2025, according to figures cited in court-related reporting. Those numbers distinguish the broader transgender inmate population from the smaller group receiving specific forms of medical treatment.
The litigation does not concern state prison systems directly. It addresses policies administered by the Federal Bureau of Prisons, which operates correctional facilities under the Justice Department.
Wednesday’s decision also comes amid a series of legal challenges to the Trump administration’s policies concerning transgender individuals.
Since returning to office in January 2025, Trump has issued directives addressing military service, federal identification documents, athletic competition and the recognition of gender identity by government agencies.
Some of those initiatives have been allowed to proceed during litigation, while others have faced injunctions in federal courts.
The Supreme Court has previously permitted certain administration restrictions to take effect on an interim basis, making Wednesday’s decision a departure from the outcome of some earlier emergency applications involving transgender policies.
However, the justices have not issued a definitive ruling establishing the constitutional or statutory limits of the federal government’s authority over gender-transition treatment in prisons.
For now, the Bureau of Prisons must continue operating under the medical treatment requirements preserved by Lamberth’s injunction. The administration remains free to pursue its legal challenge through the federal appeals process and to defend its underlying policy in district court.
The outcome of those proceedings could determine whether the government may impose broad restrictions on specific treatments or must continue using individualized medical assessments under its previous standards.
The dispute also has implications for how federal agencies justify major changes in longstanding administrative policies. Courts reviewing such decisions may require agencies to address relevant evidence, explain their reasoning and consider the consequences of reversing earlier practices.
Wednesday’s order does not determine whether the disputed medical treatments should ultimately be funded by federal taxpayers. It instead maintains existing procedures until the courts reach further conclusions about the legality of the administration’s restrictions.
With Thomas and Alito dissenting, the Supreme Court declined to intervene immediately, leaving the lower court’s protections in place and the broader legal dispute unresolved.
Original article
Comments